Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.56 |
| ▸ | TEC | P42680 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | YES1 | P07947 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | CSK | P41240 | 1/20 | 0.54 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | TXK | P42681 | 1/20 | 0.52 |
| ▸ | BLK | P51451 | 1/20 | 0.52 |
| ▸ | BMX | P51813 | 1/20 | 0.52 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15711182 | 1.00 | BTK (0.56) | BTKTECLCKEGFRRIPK2 | |
| SCHEMBL18285617 | 0.88 | BTK (0.72) | BTKTECEGFR | |
| SCHEMBL18285620 | 0.88 | BTK (0.72) | BTKTECEGFR | |
| SCHEMBL14797975 | 0.86 | BTK (0.67) | BTKTECLCKEGFRRIPK2 | |
| SCHEMBL18042993 | 0.85 | BTK (0.69) | BTK | |
| SCHEMBL18042989 | 0.85 | BTK (0.69) | BTK | |
| SCHEMBL18042991 | 0.85 | BTK (0.69) | BTK | |
| SCHEMBL14797984 | 0.84 | BTK (0.58) | BTKTECLCKEGFRRIPK2 | |
| SCHEMBL14797986 | 0.84 | BTK (0.58) | BTKTECLCKEGFRRIPK2 | |
| SCHEMBL15710567 | 0.84 | BTK (0.56) | BTKTECLCKEGFRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142099-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | BTK 7/4885TEC 10/4885LCK 9/4885 |
| US-20160257686-A1 | Purinone Derivatives as Tyrosine Kinase Inhibitors | BMX, BLK, ITK | BTK 7/4885TEC 10/4885LCK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.